New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
08:49 EDTABMDAbiomed shares overvalued, says Northland Securities
Northland believes Abiomed utilization rates for Impella are going down on both the ImpellaCP and Impella 2.5. The firm said Abiomed's story is now dependent on new site add-ons where utilization rates haven moved and sees risk to shares. The firm rates Abiomed an Underperform with a $14 price target.
News For ABMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
12:14 EDTABMDAbiomed says DOJ closes investigation into Impella 2.5
Abiomed announced that it has received confirmation from the United States Department of Justice that it has closed its investigation into the company’s marketing of the Impella 2.5 device without taking enforcement action. “We are pleased that the Department of Justice has chosen to close its investigation without pursuing any further action and that this matter is now behind us. We have always remained steadfast in our integrity and our commitment to putting our patients first,” said Abiomed CEO Michael Minogue.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use